Archives

Multimedia
Back from the dead: FierceBiotech Radio at the Battle of the Biotech Bands
FierceBiotech Radio

Here’s a special “risen-from-the-grave” episode covering this year’s Battle of the Biotech Bands, an (almost) annual Boston tradition which sees bands from the biotech industry compete to win prize money for charity.  Download the episode on iTunes or Stitcher, or listen here

Whitepaper
Considering an eTMF Solution? Industry Research Reveals the Top Benefits
Veeva

The largest survey of TMF owners reveals drivers and trends in improving inspection readiness and shortening trial time. Read more.

Webinar
Continuous Flow Chemistry for APIs and Intermediates
December 5, 2018 | 11am ET / 8am PT | Cambex

In response to an increasing market demand, Cambrex has invested in a Continuous Flow Center enabling development of previously unfeasible process steps. Register for the Cambrex webinar on Continuous Flow Chemistry for APIs and Intermediates today.

Multimedia
FierceBiotech Radio on GSK's CEO shakeup, Lilly's Alzheimer's uncertainty, and Valeant's latest disaster
FierceBiotech Radio

FiercePharma's Eric Palmer and FierceBiotech's Damian Garde discuss the pending retirement of GlaxoSmithKline CEO Andrew Witty, Eli Lilly's bold decision with a big Alzheimer's trial and Valeant Pharmaceuticals' rough week.

Download the episode on iTunes or Stitcher, or listen here.

Multimedia
FierceBiotech Radio on the FDA's new boss, Sanofi's latest shortcut, and a little 'financial innovation'
FierceBiotech Radio

FiercePharma's Eric Palmer and FierceBiotech's Damian Garde discuss the confirmation of Robert Califf as the next FDA commissioner, Sanofi's efforts to undercut Novo Nordisk in diabetes, and a novel approach to regulating drug costs. Download the episode on iTunes or Stitcher, or listen here--and be sure to subscribe

Multimedia
Pharma's TV blitz, biotech's IPO trickle, and the M&A future of Intercept Pharmaceuticals
Catalent

FiercePharma's Eric Palmer and FierceBiotech's Damian Garde discuss the rise of TV ads for specialty drugs, signs of life in the biotech IPO scene, and the case for Intercept Pharmaceuticals as a buyout target.  Download the episode on iTunes or Stitcher, or listen here--and be sure to subscribe.

Multimedia
Pharma's day on the Hill, biotech's paucity of M&A, and the gathering storm of biosimilars
FierceBiotech Radio

FiercePharma's Eric Palmer and FierceBiotech's Damian Garde discuss a bizarre congressional hearing, how biotech's slump affects the buyout climate, and a major development in the world of biosimilars.

Download the episode on iTunes or Stitcher, or listen here--and be sure to subscribe. Let us know what you think by dropping a line to [email protected]

Multimedia
Gilead's wide-open future, biotech's long winter, and Sanofi's ongoing makeover
FierceBiotech Radio

FiercePharma's Eric Palmer and FierceBiotech's Damian Garde discuss the future of Gilead Sciences, biotech's continued slump on Wall Street, and the latest move in Sanofi's efforts to right the ship.

Download the episode on iTunes or Stitcher, or listen here--and be sure to subscribe. Let us know what you think by dropping a line to [email protected]

Multimedia
Shire's byzantine Baxalta pursuit, biotech's pragmatic winter and Valeant's CEO shakeup
FierceBiotech Radio

Fierce editors discuss Shire's increasingly complicated ambition to acquire Baxalta, the changing climate of biotech venture capital and the future of Valeant Pharmaceuticals.  Click here to listen now.